Oct 23rd, 2024
Today's Late-Breaking Science
Three Late-Breaking Sessions reveal latest findings.
Late-Breaking Science
LBS.01: Late-Breaking Science 1
8:30-9:45 a.m. | Main Event I
- Effects of Intensive Blood Pressure Control in Patients With Type 2 Diabetes (BPROAD)
- Tirzepatide for Patients With Heart Failure With Preserved Ejection Fraction and Obesity: the SUMMIT Trial
- Nexiguran Ziclumeran (nex-z, also known as NTLA-2001), an Investigational in Vivo CRISPR-Based Therapy for Patients With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM): Interim Report of the Phase 1 Study
LBS.02: Late-Breaking Science 2
1:30-2:45 p.m. | Main Event I
- Catheter Ablation or Antiarrhythmic Drugs for Ventricular Tachycardia in Ischemic Cardiomyopathy (VANISH2)
- Randomized Comparison of Left Atrial Appendage Closure With Oral Anticoagulation After Catheter Ablation for Atrial Fibrillation (OPTION)
- Blinded Randomized Trial of Anticoagulation to Prevent Ischemic Stroke and Neurocognitive Impairment in Atrial Fibrillation (BRAIN AF)
LBS.03: Late-Breaking Science 3
3:15-4:30 p.m. | Main Event I
- Evaluation of Randomized Audit and Feedback to Increase Heart Failure Medication Optimization Among Primary Care Pharmacists in the Veterans Affairs Health Care System (PHARM-HF A&F Study)
- Novel AI to Assess Intracardiac Filling Pressure: The Noninvasive SEISMocardiogram in Cardiovascular Monitoring for Heart Failure I (SEISMIC-HF I) Study
- Artificial Intelligence-Based Automated ECHOcardiographic Measurements and the Workflow of Sonographers (AI-ECHO): Randomized Crossover Trial
- PanEcho: Complete AI-enabled Echocardiography Interpretation With Multitask Deep Learning
